** Shares of biotech firm ImmunoPrecise Antibodies IPA.O rise ~42% to 69 cents
** IPA says it has developed a new class of GLP-1 therapies using AI to improve diabetes treatment
** IPA's proprietary tech, called LENSai, uses patterns in biological data to create novel genetic sequences for GLP-1-like constructs
** Co says it is investigating transdermal delivery of these therapies as a non-invasive alternative to injections
** More than 300 mln shares traded, 708x times their 25-day moving avg
** IPA fell ~76% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。